Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,327 questions · 2,494 findings · 87 reviews · Oral Health

No studies found 450 · 18%GRADE not reported 1,487 · 59.6%Very low 385 · 15.4%Low 121 · 4.9%Moderate 50 · 2%High 1 · 0%

Concomitant (concurrent) chemoradiotherapy vs Radiotherapy alone

Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Concomitant (concurrent) chemoradiotherapy led to lower disease-free survival, concurrent chemoradiotherapy vs radiotherapy… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.

1 finding from 1 review

Surgery +/- radiotherapy + (adjuvant) chemotherapy vs Surgery +/- radiotherapy alone (observation or adjuvant radiotherapy only)

Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Surgery +/- radiotherapy + (adjuvant) chemotherapy led to lower disease-free survival, adjuvant concurrent chemoradiation vs… compared with surgery +/- radiotherapy alone (observation or adjuvant radiotherapy…; GRADE not reported.

1 finding from 1 review

Surgery +/- radiotherapy + (adjuvant) chemotherapy vs Surgery +/- radiotherapy alone (observation or adjuvant radiotherapy only)

Overall survival, adjuvant concomitant chemoradiotherapy vs post-surgery radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Surgery +/- radiotherapy + (adjuvant) chemotherapy probably leads to lower overall survival, adjuvant concurrent chemoradiation vs adjuvant… compared with surgery +/- radiotherapy alone (observation or adjuvant radiotherapy… (moderate certainty).

1 finding from 1 review

Induction chemotherapy plus locoregional treatment (radiotherapy and/or surgery) vs Locoregional treatment (radiotherapy and/or surgery) alone

Overall survival, induction cisplatin + 5-fluorouracil prior to concurrent chemoradiation (cisplatin) vs concurrent chemoradiation (cisplatin) · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction cisplatin + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (low certainty).

1 finding from 1 review

Chemotherapy regimen A (+/- locoregional treatment) vs Chemotherapy regimen B (+/- locoregional treatment)

Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review

Concomitant (concurrent) chemoradiotherapy vs Radiotherapy alone

Overall survival, adjuvant concomitant chemoradiotherapy vs post-surgery radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer

Concomitant (concurrent) chemoradiotherapy probably leads to lower overall survival, concurrent chemoradiotherapy vs radiotherapy alone… compared with radiotherapy alone (non-resectable tumours) (moderate certainty).

1 finding from 1 review

Intestinal trefoil factor (ITF), oral spray vs placebo

Oral mucositis (moderate to severe) · Adults receiving chemotherapy alone for colorectal cancer

Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Oral mucositis (any severity) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (any severity) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Normalcy of diet (total parenteral nutrition) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Erythropoietin mouthwash vs placebo

Oral mucositis (moderate to severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers

Erythropoietin mouthwash led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Erythropoietin mouthwash vs placebo

Oral mucositis (severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers

Erythropoietin mouthwash showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Intestinal trefoil factor (ITF), oral spray vs placebo

Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer

Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher dose (1260 to 12,600 micrograms) vs Granulocyte-macrophage colony-stimulating factor (GM-CSF), lower dose (12.6 to 126 micrograms)

Oral mucositis (severe) · breast cancer patients undergoing chemotherapy

Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.

1 finding from 1 review

Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg)

Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review

Erythropoietin mouthwash vs placebo

Oral mucositis (any severity) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers

Erythropoietin mouthwash led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Erythropoietin mouthwash vs placebo

Number of days in hospital · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers

Erythropoietin mouthwash showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.

1 finding from 1 review

Intestinal trefoil factor (ITF), oral spray vs placebo

Oral mucositis (severe) · Adults receiving chemotherapy alone for colorectal cancer

Intestinal trefoil factor (ITF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).

1 finding from 1 review